🇺🇸 FDA
Patent

US 8962637

Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors

granted A61PA61P19/00A61P19/08

Quick answer

US patent 8962637 (Bicyclic compounds and their uses as dual c-SRC/JAK inhibitors) held by Aurigene Discovery Technologies Limited expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Aurigene Discovery Technologies Limited
Grant date
Tue Feb 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61P, A61P19/00, A61P19/08, A61P35/00, A61P35/02